Creo Medical Group PLC First use of Speedboat in the US (1927N)
January 16 2019 - 2:00AM
UK Regulatory
TIDMCREO
RNS Number : 1927N
Creo Medical Group PLC
16 January 2019
Creo Medical Group plc
("Creo" or the "Company")
First use of Speedboat in the US
Successful patient treatments performed by two US doctors
Creo Medical Group plc (AIM: CREO), a medical device company
focused on the emerging field of surgical endoscopy, announces the
successful first treatment of patients in the US using its
Speedboat device powered by the Company's CROMA electrosurgery
advanced energy platform.
As part of the Company's strategy to establish a
training-centric commercialisation programme in the US two
gastrointestinal surgeons from the same hospital were trained in
the use of the Speedboat device over the weekend and each performed
successful operations on patients this week. The two procedures
were performed in both the upper and lower gastrointestinal (GI)
tract respectively.
The Company expects to increase the number of trained clinicians
in the US as the roll-out of the Creo Clinical Education Programme
continues and looks forward to updating shareholders on further
positive progress in this key market.
Speedboat is the first device developed for use with Creo's
CROMA generator, an electrosurgical platform that combines bipolar
radiofrequency for precise, localised cutting and microwave for
controlled coagulation. The Speedboat harnesses the cut and
coagulation of the generator to enable the removal of cancerous and
pre-cancerous GI growths.
Patients have now been successfully treated using the Speedboat
device powered by Creo's CROMA platform in the UK, South Africa,
Mainland Europe and the US.
Craig Gulliford, Creo's Chief Executive Officer, commented:
"The US is clearly a key market for the Company and the
successful completion of the first procedures in the United States
is another important milestone for us. Over the next few weeks and
months we expect to see our Clinical Education Programme expand in
the US and we will continue to update shareholders as our
training-led commercialisation strategy advances."
Creo Medical Group plc
Richard Rees (CFO) +44 (0)129 160 6005
Cenkos Securities +44 (0)20 7397 8900
Stephen Keys/Mark Connelly (NOMAD)
Michael Johnson / Russell Kerr (Sales)
Walbrook PR Ltd Tel: +44 (0)20 7933 8780 or creo@walbrookpr.com
Paul McManus Mob: +44 (0)7980 541 893
Helen Cresswell Mob: +44 (0)7841 917 679
This announcement contains inside information.
About Creo Medical
Creo Medical, founded in 2003, is a medical device company
focused on the development and commercialisation of minimally
invasive surgical devices, by bringing advanced energy to
endoscopy. The Company's mission is to improve patient outcomes by
applying microwave and RF energy to surgical endoscopy. Creo has
developed CROMA, an electrosurgical advanced energy platform that
combines bipolar radiofrequency for precise localised cutting and
microwave for controlled coagulation. This technology provides
clinicians with flexible, accurate and controlled surgical
solutions.
The Company's strategy is to bring its CROMA platform to market
through a suite of medical devices which the Company has designed,
initially for the emerging field of GI therapeutic endoscopy, an
area with high unmet needs. The CROMA platform will be developed
further for bronchoscopy and laparoscopy procedures. The Company
believes its technology can impact the landscape of surgery and
endoscopy by providing a safer, less-invasive and more
cost-efficient option of treatment.
For more information about Creo Medical please see our website,
investors.creomedical.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
MSCBAMLTMBBBBBL
(END) Dow Jones Newswires
January 16, 2019 02:00 ET (07:00 GMT)
Creo Medical (LSE:CREO)
Historical Stock Chart
From Apr 2024 to May 2024
Creo Medical (LSE:CREO)
Historical Stock Chart
From May 2023 to May 2024